The Comparative Efficacy of Non-ergot Dopamine Agonist and Potential Risk Factors for Motor Complications and Side Effects From NEDA Use in Early Parkinson's Disease: Evidence From Clinical Trials

BACKGROUND/OBJECTIVES: Non-ergot dopamine agonist (NEDA) are recommended as the first-line treatment for patients with early Parkinson's disease (PD) because of their efficacy in treating PD motor symptoms. However, systematic evaluations of the risk of motor complications induced by NEDA and r...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Chunxiao, Guo, Hongji, Xu, Yingshan, Li, Luping, Li, Xinyu, Tang, Chunzhi, Chen, Dongfeng, Zhu, Meiling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Aging Neuroscience
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9074827/
https://www.ncbi.nlm.nih.gov/pubmed/35527736
http://dx.doi.org/10.3389/fnagi.2022.831884

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9074827/
https://www.ncbi.nlm.nih.gov/pubmed/35527736
http://dx.doi.org/10.3389/fnagi.2022.831884

Ejemplares similares